Thousands of people who suffered devastating personal losses from the opioid crisis and who filed claims against Purdue Pharma opioid during its bankruptcy proceedings are now discovering that the compensation they believed was coming to them is slipping away not because their suffering was not real or not caused by opioids but because they cannot produce the specific pharmaceutical manufacturer documentation that the settlement's administrators are requiring as proof that the pills they or their loved ones consumed were made by Purdue rather than by a generic competitor, a requirement that has proved impossible for many claimants to satisfy years after the events in question and after the records that might have established the necessary proof have been routinely destroyed by the pharmacies, doctors, hospitals, and insurers that held them. Reuters analyzed the vast bankruptcy record built over six years of proceedings, reviewing hundreds of legal filings, more than 100 letters from people seeking compensation, and conducting interviews with eight victims and lawyers close to the case, finding that a deal hailed by both Purdue and plaintiffs' lawyers as a historic victory for opioid crisis victims has in practice erected documentation barriers that many claimants are finding insurmountable despite years of waiting for a justice system process that they were told would deliver meaningful accountability and compensation for their losses. The approximately $865 million earmarked for individual victims in the Purdue settlement represents the last and best chance that opioid crisis survivors and families of those who died from opioid-related causes will have to receive any individual compensation, as the sprawling litigation that once targeted nearly every major opioid manufacturer, distributor, and pharmacy chain across the country is largely concluded and no comparable fund directed at individual victims is expected to emerge from the remaining legal proceedings.

Mary Anne Blanton is among the people who may receive nothing from the settlement despite a family history that appears to fit squarely within the human catastrophe that Purdue Pharma's aggressive and misleading marketing of OxyContin helped create. Her mother Tammy Blanton's life unraveled over years of taking opioids initially prescribed for migraines, with the drugs leaving her increasingly isolated, unemployed, and estranged from her family in a pattern of progressive deterioration that became tragically familiar to millions of American families during the years when OxyContin and similar drugs were being prescribed at rates that pharmaceutical executives, regulators, and physicians later acknowledged were wildly out of proportion to any legitimate medical need. Tammy received opioid prescriptions from multiple providers for decades, averaging more than 200 pills a month during a two-year period, before dying at age 58 in 2017 when a medical examiner concluded that oxycodone and extended-release morphine, combined with alcohol and anti-anxiety medications, contributed to her accidental death. Mary Anne filed a claim in the Purdue bankruptcy believing her mother's documented history of opioid use and its catastrophic consequences would qualify her for compensation, only to learn years later that she cannot prove which manufacturer produced the specific pills her mother consumed, a distinction that the settlement's administrators treat as legally determinative despite the fact that Purdue developed and first marketed both OxyContin and extended-release morphine before other companies obtained approval to sell generic versions of the same drugs.

The scale of the documentation problem confronting opioid victims who filed claims in the Purdue bankruptcy is reflected in the numbers that have emerged from the court proceedings overseeing the settlement's administration. More than 40 percent of the approximately 140,000 claims filed before the September 2021 deadline have already been rejected by the federal judge overseeing the bankruptcy. When Purdue asked the court in January to expunge more than 57,000 claims from people who had not responded to the trustee's documentation request, hundreds of victims sent letters to the court describing not only the practical impossibility of producing the required records but basic confusion about how the settlement process worked and what they needed to do to preserve their claims, with many expressing a sense of abandonment by a legal system that had encouraged them to file claims and then years later imposed requirements that they had no meaningful ability to satisfy. The judge agreed to dismiss nearly all of the 57,000 claims despite acknowledging the frustration and bureaucratic complexity that victims had described, a ruling that illustrates the gap between the human reality of the opioid crisis's victims and the procedural requirements of a corporate bankruptcy system that was not designed with their circumstances in mind.

How the Purdue Pharma Bankruptcy Created a Documentation Trap for Opioid Victims

The requirement that individual claimants prove that Purdue specifically manufactured the opioids that harmed them or their loved ones was embedded in the bankruptcy plan that Purdue negotiated with its creditors, reflecting the company's longstanding legal position that it should be held responsible only for harms that are directly and specifically traceable to its own products rather than to the broader opioid epidemic that victims and their advocates argue Purdue's marketing practices ignited and sustained regardless of which manufacturer produced the specific pill that any individual consumed on any given day. This position carries a certain formal legal coherence in the context of product liability law but sits in profound tension with the reality of how prescription opioids actually worked their way through the American healthcare system during the years of peak prescribing, when patients received prescriptions listing a drug name rather than a manufacturer, pharmacies routinely substituted generic products for brand-name prescriptions to reduce costs, insurance companies steered patients toward generics through formulary rules, and the distinction between a Purdue product and a generic equivalent was entirely invisible to the patients and families who were simply trying to manage pain with the medications their doctors prescribed.

The practical challenge of proving manufacturer-specific provenance years or decades after the relevant prescriptions were filled is compounded by the routine destruction of the records that might have established the necessary proof. Doctors' offices typically list the drug prescribed in patient records without identifying the manufacturer, pharmacies change their suppliers over time and may have dispensed different manufacturers' products on different occasions when filling what appeared to be the same ongoing prescription, and neither pharmacies nor doctors nor hospitals nor insurers are required under the laws of most states to retain records for more than a few years. By the time the Purdue bankruptcy trustee made the first formal request for manufacturer documentation in May 2025, nearly four years after the original claims deadline had passed and well over a decade after many of the relevant prescriptions had been filled, the window for obtaining the requested records from the institutions that had once held them had long since closed for most claimants. The 60-day deadline the trustee set for producing these records gave people a two-month window to accomplish what years of searching had already shown was in many cases impossible, a timeline that strikes victims and their advocates as reflecting a fundamental misunderstanding of the circumstances facing the people the settlement was supposed to help.

An earlier version of the Purdue bankruptcy plan had included a pathway to compensation that acknowledged this documentation reality by allowing people without prescription records to qualify for a $3,500 payment if they signed a sworn affidavit affirming their use of Purdue opioids, with larger payments of up to $48,000 available to those who could produce records and demonstrate more serious harms. But the extended appeals process that kept the Purdue bankruptcy in litigation for years, eventually reaching the United States Supreme Court, produced a reworked deal that eliminated the affidavit pathway and limited compensation only to those who could produce documentation, a change that was not discussed openly in court proceedings and that ProPublica first reported publicly. Ed Neiger, an attorney who helped represent a group of approximately 30,000 victims, described the negotiating reality behind this change in terms that illuminate the compromises that characterized the settlement process, acknowledging that plaintiffs' lawyers sought to make documentation requirements as flexible as possible but encountered demands from other parties in the bankruptcy that claimants provide proof comparable to what would be required in traditional litigation, leaving the choice between accepting the documentation requirement or blowing up the settlement entirely.

What Real Victims Are Experiencing as Documentation Requirements Prove Impossible to Meet

The human stories behind the aggregate statistics of rejected claims illustrate the specific and often cruelly ironic ways in which the documentation requirement intersects with the realities of opioid addiction and its aftermath to create barriers that are most difficult for the people most severely harmed by the crisis. Mary Anne Blanton has spent years searching for records from the doctors, hospitals, and pharmacies that treated her mother, finding that her primary care physician had legally destroyed patient records, that hospital records she managed to obtain did not identify the pill manufacturer, and that records from Arizona's Medicaid program, which paid for most of her mother's prescriptions, were inaccessible because of documentation requirements tied to proving next-of-kin status and privacy regulations that treat deceased patients' records with the same confidentiality protections as living ones regardless of the circumstances of the inquiry. She articulated the fundamental absurdity of the manufacturer-specific requirement from the perspective of a grieving daughter trying to navigate a corporate bankruptcy system: to her it is irrelevant whether Purdue manufactured the specific prescription that killed her mother because Purdue told everyone that opioids were safe and non-addictive and created the epidemic in which her mother became trapped.

Michele Capozzi-Pollock, a 59-year-old Massachusetts woman whose husband died after years of opioid use, represents another dimension of the documentation barrier's cruelty, the assumption embedded in the settlement process that people devastated by addiction and its consequences will have maintained the kind of meticulous pharmaceutical records that even organized and healthy people rarely keep. When she was told that prescription pill bottles could be used as documentation, she responded with laughter at the practical absurdity of expecting someone to have saved sixteen years of prescription bottles, a reaction that captures how thoroughly disconnected the settlement's evidentiary requirements are from the lived reality of families managing a family member's long-term addiction crisis. She was ultimately informed that her claim would be denied because she had not responded to the documentation request sent to her deceased husband three years after his death, a bureaucratic failure of address management that resulted in the loss of her ability to participate in the only compensation fund that will ever exist for people harmed by the opioid crisis. Michael Galipeau, a 42-year-old New York man who became addicted to opioids following a broken wrist injury in 2007 and has since rebuilt his life to the point of counseling others in addiction recovery, found out about the rejection of his claim only by reaching page 3,024 of a 17,101-page PDF attachment to an email he received nearly six years after initially filing his claim, a discovery process so absurd in its bureaucratic scale that it would be comic if it were not occurring at the conclusion of a decade-long wait for justice.

The contrast between those who will receive compensation and those who will receive nothing illustrates that success in the Purdue settlement often reflects not the severity of harm suffered but the practical resources and organizational capacity that survivors happened to have available in the aftermath of catastrophic loss. Jill Cichowicz, who lost her twin brother Scott to an overdose in 2017, expects to qualify for a payment because Scott kept detailed personal notes about his medications, her family had the resources to hire an investigator, and they preserved pill bottles bearing Purdue's name as manufacturer after his death, advantages that she readily acknowledges most families in addiction crisis do not have. Her observation that people battling addiction are just trying to survive rather than maintaining copious records and spreadsheets captures in a single sentence why the documentation requirement that the settlement imposes systematically disadvantages the most severely harmed claimants in favor of those whose circumstances gave them the capacity to maintain pharmaceutical records through years of personal tragedy.

What the Purdue Settlement Failure Means for Opioid Crisis Accountability and Future Victims

The Purdue Pharma settlement's failure to deliver meaningful compensation to the majority of individual victims who filed claims represents a systemic failure that extends beyond the specific procedural choices made in a single corporate bankruptcy to reflect broader questions about whether the American legal system's mechanisms for addressing mass corporate harms are capable of delivering justice to ordinary individuals rather than primarily to the lawyers, state governments, and institutional parties who have the resources and expertise to navigate complex proceedings effectively. The $57 billion in settlements generated by the broader opioid litigation has been mostly directed to state and local governments rather than to individuals, reflecting the legal architecture of public nuisance claims and government enforcement actions that dominated the litigation strategy pursued by state attorneys general and municipal lawyers who had both the resources to litigate effectively and the legal standing to pursue the largest damage theories available under applicable law. For individual victims, the Purdue settlement's $865 million individual compensation fund represented the only significant pool of money ever directed at personal harm from the opioid crisis, and the documentation requirements that are eliminating tens of thousands of claims from that fund are ensuring that the actual distribution falls far short of the historic achievement that both Purdue's lawyers and plaintiffs' representatives claimed to have negotiated when the deal was announced.

Purdue's scheduled sentencing on April 28 in the federal criminal case in which the company has twice pleaded guilty to charges related to its marketing of OxyContin provides a final formal moment of legal accountability for an organization that admitted to misleading regulators, doctors, and patients about addiction risks and engaging in illegal practices to boost opioid sales over decades. The judge overseeing the sentencing delayed the proceeding by one week specifically to allow victims who wanted to speak about Purdue's conduct to participate in person, an accommodation that acknowledges the human dimension of the corporate criminal case while also illustrating the gap between the formal legal accountability being imposed on the corporate entity and the practical absence of meaningful individual accountability for the Sackler family members who owned and directed the company during the years of most aggressive and harmful marketing. Members of the Sackler family referred Reuters to Purdue for comment on the documentation issues affecting individual claimants, and Purdue declined multiple requests for comment, a combination of responses that reflects the posture of parties who have formally accepted legal accountability in negotiated proceedings while remaining unwilling to engage publicly with the specific ways in which that settlement is failing the people it was supposed to serve.

The individuals whose claims are rejected through the documentation process have limited practical recourse beyond the settlement, with Neiger noting that individual lawsuits against Purdue or the Sackler family would likely take years, cost significant sums, and require far more detailed proof than the bankruptcy settlement demands, with no assurance of success and no precedent of any individual ever having successfully sued the Sacklers or Purdue over a personal opioid addiction. The closure of the litigation that once targeted manufacturers, distributors, and pharmacy chains means there are no other significant legal proceedings in which individual victims might seek compensation, making the Purdue fund both the first and last meaningful opportunity for personal accountability in the legal reckoning with the opioid crisis. For families like Mary Anne Blanton's, who believed that the bankruptcy process represented their long-delayed chance to have a legal system acknowledge and compensate for what happened to someone they loved, the documentation requirements that stand between them and any payment represent not just a procedural disappointment but a fundamental failure of a justice system that proved more capable of compensating institutions than the human beings whose suffering was the underlying reality that gave the entire legal proceeding its moral justification.